Antibody response in individuals infected with SARS-CoV-2 early after the first dose of the BNT162b2 mRNA vaccine

Published:August 06, 2021DOI:https://doi.org/10.1016/j.jinf.2021.08.008

      Highlights

      • SARS-CoV-2 infection after the first BNT162b2 dose does not boost antibody response.
      • A postponed second dose induced antibody titres similar to those in naïve vaccinees.
      • We advise a second vaccine dose for individuals infected early after the first dose.

      Keywords

      To read this article in full you will need to make a payment

      Subscribe:

      Subscribe to Journal of Infection
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Tré-Hardy M.
        • Cupaiolo R.
        • Wilmet A.
        • Beukinga I.
        • Blairon L.
        Waning antibodies in SARS-CoV-2 naïve vaccinees: results of a three-month interim analysis of ongoing immunogenicity and efficacy surveillance of the mRNA-1273 vaccine in healthcare workers.
        J Infect. 2021; (Jun 20S0163-4453(21)00314-5)https://doi.org/10.1016/j.jinf.2021.06.017
        • Krammer F.
        • Srivastava K.
        • Alshammary H.
        • Amoako A.A.
        • Awawda M.H.
        • Beach K.F.
        • et al.
        Antibody responses in seropositive persons after a single dose of SARS-CoV-2 mRNA vaccine.
        N Engl J Med. 2021; https://doi.org/10.1056/NEJMc2101667
        • Gobbi F.
        • Buonfrate D.
        • Moro L.
        • Rodari P.
        • Piubelli C.
        • Caldrer S.
        • et al.
        Antibody response to the BNT162b2 mRNA COVID-19 vaccine in subjects with prior SARS-CoV-2 infection.
        Viruses. 2021; 13: 422https://doi.org/10.3390/v13030422
        • Buonfrate D.
        • Piubelli C.
        • Gobbi F.
        • Martini D.
        • Bertoli G.
        • Ursini T.
        • et al.
        Antibody response induced by the BNT162b2 mRNA COVID-19 vaccine in a cohort of health-care workers, with or without prior SARS-CoV-2 infection: a prospective study.
        Clin Microbiol Infect. 2021; https://doi.org/10.1016/j.cmi.2021.07.024
        • Khoury D.S.
        • Cromer D.
        • Reynaldi A.
        • Schlub T.E.
        • Wheatley A.K.
        • Juno J.A.
        • et al.
        Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection.
        Nat Med. 2021; 27: 1205-1211https://doi.org/10.1038/s41591-021-01377-8
        • Krammer F.
        A correlate of protection for SARS-CoV-2 vaccines is urgently needed.
        Nat Med. 2021; 27: 1147-1148https://doi.org/10.1038/s41591-021-01432-4
        • Lustig Y.
        • Zuckerman N.
        • Nemet I.
        • Atari N.
        • Kliker L.
        • Regev-Yochay G.
        • et al.
        Neutralising capacity against delta (B.1.617.2) and other variants of concern following comirnaty (BNT162b2, BioNTech/Pfizer) vaccination in health care workers, Israel.
        Euro Surveill. 2021; 26https://doi.org/10.2807/1560-7917.ES.2021.26.26.2100557
        • Lustig Y.
        • Sapir E.
        • Regev-Yochay G.
        • Cohen C.
        • Fluss R.
        • Olmer L.
        • et al.
        BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers.
        Lancet Respir Med. 2021; (S2213-2600(21)00220-4)https://doi.org/10.1016/S2213-2600(21)00220-4